Myriad Genetics director proposes sale of 6,100 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mark Steven Davis, a director of Myriad Genetics Inc., gave notice of a proposed sale of 6,100 common shares, with an aggregate market value of $34,251.50 and an approximate sale date of November 18, 2026. The listed shares came from restricted stock vesting: 2,100 shares acquired on December 10, 2025 and 4,000 shares acquired on June 4, 2026.
Key Figures
Key Terms
Restricted Stock Vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.